Compare Novo Nordisk A/S (NVO) vs Western Alliance Bancorporation (WAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Western Alliance Bancorporation — how do they compare? Novo Nordisk A/S trades at $44.69 (market cap $200.69B), while Western Alliance Bancorporation trades at $79.37 (market cap $8.72B). The key difference: Novo Nordisk A/S is far larger — about 23× Western Alliance Bancorporation's market cap, and Novo Nordisk A/S pays the higher dividend (3.98%). Which is the better fit depends on your goals.
| NVO | WAL | |
|---|---|---|
Market Cap | $200.69B | $8.72B |
Sector | Health | Financials |
52-Week High | $63.98 | $96.08 |
52-Week Low | $35.29 | $66.70 |
Enterprise Value | $215.49B | — |
Dividend Yield | 3.98% | 2.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $45.16, down 3.09% today, with bearish technical signals but strong fundamentals. The stock shows robust profitability with 35.35% net margin and 59.82% ROE, supported by consistent earnings beats. Recent developments include positive pediatric obesity trial results for semaglutide and Wegovy pill launch in Germany. Cash flow remains healthy with $10.81B net inflow in 2025, though 2026 projections show a decline.
NVO presents a mixed outlook with strong fundamental metrics offset by technical weakness and competitive pressures. Investment opportunity lies in the expanding GLP-1 market and pipeline developments, while risks include market share loss to Eli Lilly and failed cardiovascular drug trials. Analyst consensus leans bullish with 57.9% buy ratings, but recent prescription slowdown concerns warrant caution.
Western Alliance Bancorporation (WAL) trades at $79.94, down 1.25% on the day, with a bearish technical signal despite strong fundamentals. The bank reported Q2 2026 earnings that met revenue expectations but slightly missed EPS estimates, while maintaining robust profitability with a 25.43% net income margin and 13.43% ROE. Recent developments include the launch of WA VenueX™ digital asset platform and recognition as Arizona's #1 bank by Forbes.
WAL presents a compelling value opportunity with a P/E of 9.02 and strong analyst support (79% buy ratings, $93.86 consensus target), though negative operating cash flow and bearish technical indicators warrant caution. The stock offers 17% upside to consensus target but faces headwinds from declining cash flow and mixed earnings performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Western Alliance Bancorporation
Western Alliance Bancorporation is a top-performing bank holding company that operates a dual business model: high-touch regional banking and specialized national business lines. It serves niche industries—including technology, life sciences, and homeowners associations—providing sophisticated commercial lending and treasury solutions that bridge the gap between regional service and national scale.
Read more on WAL →
